A
Avraham Pharmaceuticals
A pharmaceutical company that develops novel products for the treatment and prevention of neurodegenerative disorders
About Avraham Pharmaceuticals
Avraham Pharmaceuticals, founded in 2010, is a privately held pharmaceutical company focused on developing innovative treatments for neurodegenerative diseases. The company's primary product candidate, Ladostigil, is designed to treat Mild Cognitive Impairment (MCI), a condition often seen as a precursor to Alzheimer's disease. Ladostigil is a multifunctional drug that aims to protect nerve cells by reducing oxidative stress (damage caused by free radicals) and microglial activation (inflammation in the brain). The drug is currently in Phase 2 clinical trials, which means it is being tested on a larger group of patients to evaluate its effectiveness and safety.
Read full description
Avraham Pharmaceuticals operates in the biopharmaceutical market, specifically targeting neurodegenerative disorders. Their clients include healthcare providers, research institutions, and potentially patients who suffer from MCI and other related conditions. The company has successfully raised $18 million to fund its clinical trials and development efforts. Key shareholders include prominent entities such as Yissum, Pontifax, CBI, and Technion TRDF.
The business model of Avraham Pharmaceuticals revolves around the development and eventual commercialization of Ladostigil. By advancing through clinical trials and obtaining regulatory approval, the company aims to bring Ladostigil to market, where it can be prescribed by doctors and sold through pharmacies. Revenue will primarily come from the sales of Ladostigil, once it is approved and launched.
In summary, Avraham Pharmaceuticals is making significant strides in the fight against neurodegenerative diseases with its promising drug candidate, Ladostigil. The company is well-funded and supported by key stakeholders, positioning it strongly in the biopharmaceutical market.
At a glance
- Founded
- 2010
- Headquarters
- Rehovot, Israel
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Pontifax Funds
Yissum Research Development
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avraham Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avraham Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.